<DOC>
	<DOC>NCT01753310</DOC>
	<brief_summary>The purpose of the protocol is to evaluate the efficacy and safety of Dysport® using 2 mL dilution compared with placebo for the treatment of Cervical Dystonia.</brief_summary>
	<brief_title>Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.</brief_title>
	<detailed_description />
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Primary diagnosis of Cervical Dystonia at least 9 months since onset and either previously untreated with botulinum toxin or currently treated with Botox at a total dosing range of 100200 U and ≤60 U in the sternocleidomastoid muscle at the last injection cycle, and having had a satisfactory treatment response in the principal investigator's judgment during the last two sequential Botox treatment cycles. TWSTRS total score≥ 20; TWSTRSseverity subscale score&gt; 10; In apparent remission from Cervical Dystonia Diagnosis of pure retrocollis or pure anterocollis For nonnaïve subjects, previous poor response to either of the last two Botox treatments Known requirement of &lt;100U or &gt;200U of Botox injected into the neck muscles</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>